PMID- 10613641
OWN - NLM
STAT- MEDLINE
DCOM- 19991229
LR  - 20240229
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 82
IP  - 6
DP  - 1999 Dec
TI  - The effects of unfractionated heparin on survival in patients with malignancy--a 
      systematic review.
PG  - 1600-4
AB  - Clinical and experimental studies have suggested that unfractionated heparin 
      (UFH) effects malignancy progression. We reviewed all published clinical reports 
      concerning the effects of UFH, as compared to no treatment on survival of cancer 
      patients. Studies were classified on methodological strength and subdivided as to 
      whether therapeutic or prophylactic dosages of UFH were used. Mortality rates 
      after 3 years were extracted or calculated. One randomized study that evaluated 
      the use of UFH in therapeutic dosages in patients with small cell lung carcinoma 
      reported on an improved survival (odds ratio (OR) 0.64; 95% confidence interval 
      (CI): 0.25 to 1.62). A detrimental effect was observed in 2 randomized studies 
      which investigated the effects of intraportal UFH treatment in a prophylactic 
      dose after surgery for gastrointestinal cancer (OR 1.66; 95% CI: 1.02 to 2.71). 
      In contrast, level 2 studies in which either therapeutic or prophylactic dosages 
      of UFH on mortality of patients with gastrointestinal cancer were evaluated, 
      showed OR of 0.58 (95% CI; 0.11-3.13) and 0.65 (95% CI 0.51 to 0.84), 
      respectively. We conclude that there is no convincing evidence of either 
      positively or negatively effects of UFH on survival of patients with malignancy.
FAU - Smorenburg, S M
AU  - Smorenburg SM
AD  - Department of Vascular Medicine, Academic Medical Center, University of 
      Amsterdam, The Netherlands. s.m.smorenburg@amc.uva.nl
FAU - Hettiarachchi, R J
AU  - Hettiarachchi RJ
FAU - Vink, R
AU  - Vink R
FAU - Buller, H R
AU  - Buller HR
LA  - eng
PT  - Journal Article
PT  - Systematic Review
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Anticoagulants)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Humans
MH  - *Anticoagulants/adverse effects/therapeutic use
MH  - *Heparin/adverse effects/therapeutic use
MH  - Meta-Analysis as Topic
MH  - *Neoplasms/drug therapy/mortality
MH  - Randomized Controlled Trials as Topic
MH  - Survival Analysis
EDAT- 1999/12/29 00:00
MHDA- 1999/12/29 00:01
CRDT- 1999/12/29 00:00
PHST- 1999/12/29 00:00 [pubmed]
PHST- 1999/12/29 00:01 [medline]
PHST- 1999/12/29 00:00 [entrez]
AID - 99121600 [pii]
PST - ppublish
SO  - Thromb Haemost. 1999 Dec;82(6):1600-4.